Treatment patterns and clinical outcomes in acute myeloid leukemia patients who are not eligible for intensive induction chemotherapy: A real-world study from Latin-America

Introduction. There is a knowledge gap concerning patients with acute myeloid leukemia (AML) who are not eligible for intensive induction chemotherapy; this, together with a recent increase in the incidence in Latin America, encloses a need. Through real-world evidence, we describe and compare the r...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medicina y Laboratorio 2023-10, Vol.27 (4), p.315-332
Hauptverfasser: Gálvez-Cárdenas, Kenny Mauricio, Enciso-Olivera, Leonardo José, Samanez-Figari, César Augusto, Quintana-Truyenque, Shirley, Castillo-Ríos, Benito Arturo, Quintero-Vega, Guillermo Enrique, Arrieta-López, Elizabeth, Pinto-Gómez, Alexis Javier, Aruachan-Vesga, Sandra, Durán-Sánchez, María Isabel, Espino-Lopéz, Germán
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 332
container_issue 4
container_start_page 315
container_title Medicina y Laboratorio
container_volume 27
creator Gálvez-Cárdenas, Kenny Mauricio
Enciso-Olivera, Leonardo José
Samanez-Figari, César Augusto
Quintana-Truyenque, Shirley
Castillo-Ríos, Benito Arturo
Quintero-Vega, Guillermo Enrique
Arrieta-López, Elizabeth
Pinto-Gómez, Alexis Javier
Aruachan-Vesga, Sandra
Durán-Sánchez, María Isabel
Espino-Lopéz, Germán
description Introduction. There is a knowledge gap concerning patients with acute myeloid leukemia (AML) who are not eligible for intensive induction chemotherapy; this, together with a recent increase in the incidence in Latin America, encloses a need. Through real-world evidence, we describe and compare the results of the different treatment strategies within this context. Methodology. This is a longitudinal, descriptive, retrospective study of a cohort of Latin American patients with AML not eligible for intensive induction chemotherapy, treated with low-intensity chemotherapy or with the best supportive care alone between January 1, 2015, to December 31, 2018. Results. Of a total of 125 patients (median age 74.8 years), the majority received low-intensity chemotherapy (78.4%). The median time in months of overall survival (9.2), progression-free survival (4.8), and time to treatment failure (3.8) were longer in patients receiving hypomethylating agents. Additionally, better results were observed with low-intensity chemotherapy (complete response 11.2% and stable disease 17.3%) compared to the best supportive care alone. Conclusion. We deliver a real-world standpoint of Latin American patients with AML who are not eligible for intensive induction chemotherapy. Our findings pave the first steps of the way to describe, understand, and support informed decision-making processes in our region.
doi_str_mv 10.36384/01232576.683
format Article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_36384_01232576_683</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_36384_01232576_683</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1473-eb7e9d48a8e192c0be9eb2e2bb7fb40dc30e34c3e869fe1ed535515ac7f5abbf3</originalsourceid><addsrcrecordid>eNo1kMtKAzEUhoMoWLRL9-cFUjOTuborxRsU3NT1kGRObDSTlCRjmXfyIZ16WZ0DP__Hz0fITcZWvOJNccuynOdlXa2qhp-RRV4yRuuMVedkcYroKbskyxjfGWN5m_OGsQX52gUUaUCX4CBSwuAiCNeDssYZJSz4MSk_YATjQKgxIQwTWm96sDh-4GDEqWhmQITj3oMICM4nQGvejLQI2oe5m9BF84nz148qGe9A7XHwaY9BHKY7WMO8w9KjD7aHmMZ-Ah38ANuZ7eh6wDCvuSYXWtiIy797RV4f7nebJ7p9eXzerLdUZUXNKcoa275oRINZmysmsUWZYy5lrWXBesUZ8kJxbKpWY4Z9ycsyK4WqdSmk1PyK0F-uCj7GgLo7BDOIMHUZ635sd_-2u9k2_wZ9qHdp</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Treatment patterns and clinical outcomes in acute myeloid leukemia patients who are not eligible for intensive induction chemotherapy: A real-world study from Latin-America</title><source>DOAJ Directory of Open Access Journals</source><source>Alma/SFX Local Collection</source><creator>Gálvez-Cárdenas, Kenny Mauricio ; Enciso-Olivera, Leonardo José ; Samanez-Figari, César Augusto ; Quintana-Truyenque, Shirley ; Castillo-Ríos, Benito Arturo ; Quintero-Vega, Guillermo Enrique ; Arrieta-López, Elizabeth ; Pinto-Gómez, Alexis Javier ; Aruachan-Vesga, Sandra ; Durán-Sánchez, María Isabel ; Espino-Lopéz, Germán</creator><creatorcontrib>Gálvez-Cárdenas, Kenny Mauricio ; Enciso-Olivera, Leonardo José ; Samanez-Figari, César Augusto ; Quintana-Truyenque, Shirley ; Castillo-Ríos, Benito Arturo ; Quintero-Vega, Guillermo Enrique ; Arrieta-López, Elizabeth ; Pinto-Gómez, Alexis Javier ; Aruachan-Vesga, Sandra ; Durán-Sánchez, María Isabel ; Espino-Lopéz, Germán</creatorcontrib><description>Introduction. There is a knowledge gap concerning patients with acute myeloid leukemia (AML) who are not eligible for intensive induction chemotherapy; this, together with a recent increase in the incidence in Latin America, encloses a need. Through real-world evidence, we describe and compare the results of the different treatment strategies within this context. Methodology. This is a longitudinal, descriptive, retrospective study of a cohort of Latin American patients with AML not eligible for intensive induction chemotherapy, treated with low-intensity chemotherapy or with the best supportive care alone between January 1, 2015, to December 31, 2018. Results. Of a total of 125 patients (median age 74.8 years), the majority received low-intensity chemotherapy (78.4%). The median time in months of overall survival (9.2), progression-free survival (4.8), and time to treatment failure (3.8) were longer in patients receiving hypomethylating agents. Additionally, better results were observed with low-intensity chemotherapy (complete response 11.2% and stable disease 17.3%) compared to the best supportive care alone. Conclusion. We deliver a real-world standpoint of Latin American patients with AML who are not eligible for intensive induction chemotherapy. Our findings pave the first steps of the way to describe, understand, and support informed decision-making processes in our region.</description><identifier>ISSN: 0123-2576</identifier><identifier>EISSN: 2500-7106</identifier><identifier>DOI: 10.36384/01232576.683</identifier><language>eng</language><ispartof>Medicina y Laboratorio, 2023-10, Vol.27 (4), p.315-332</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1473-eb7e9d48a8e192c0be9eb2e2bb7fb40dc30e34c3e869fe1ed535515ac7f5abbf3</cites><orcidid>0000-0003-4002-1423 ; 0000-0001-5540-1969 ; 0000-0002-3671-6911 ; 0000-0002-1879-2486 ; 0000-0003-1192-9053 ; 0000-0003-3755-9513 ; 0000-0002-3714-4476</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27901,27902</link.rule.ids></links><search><creatorcontrib>Gálvez-Cárdenas, Kenny Mauricio</creatorcontrib><creatorcontrib>Enciso-Olivera, Leonardo José</creatorcontrib><creatorcontrib>Samanez-Figari, César Augusto</creatorcontrib><creatorcontrib>Quintana-Truyenque, Shirley</creatorcontrib><creatorcontrib>Castillo-Ríos, Benito Arturo</creatorcontrib><creatorcontrib>Quintero-Vega, Guillermo Enrique</creatorcontrib><creatorcontrib>Arrieta-López, Elizabeth</creatorcontrib><creatorcontrib>Pinto-Gómez, Alexis Javier</creatorcontrib><creatorcontrib>Aruachan-Vesga, Sandra</creatorcontrib><creatorcontrib>Durán-Sánchez, María Isabel</creatorcontrib><creatorcontrib>Espino-Lopéz, Germán</creatorcontrib><title>Treatment patterns and clinical outcomes in acute myeloid leukemia patients who are not eligible for intensive induction chemotherapy: A real-world study from Latin-America</title><title>Medicina y Laboratorio</title><description>Introduction. There is a knowledge gap concerning patients with acute myeloid leukemia (AML) who are not eligible for intensive induction chemotherapy; this, together with a recent increase in the incidence in Latin America, encloses a need. Through real-world evidence, we describe and compare the results of the different treatment strategies within this context. Methodology. This is a longitudinal, descriptive, retrospective study of a cohort of Latin American patients with AML not eligible for intensive induction chemotherapy, treated with low-intensity chemotherapy or with the best supportive care alone between January 1, 2015, to December 31, 2018. Results. Of a total of 125 patients (median age 74.8 years), the majority received low-intensity chemotherapy (78.4%). The median time in months of overall survival (9.2), progression-free survival (4.8), and time to treatment failure (3.8) were longer in patients receiving hypomethylating agents. Additionally, better results were observed with low-intensity chemotherapy (complete response 11.2% and stable disease 17.3%) compared to the best supportive care alone. Conclusion. We deliver a real-world standpoint of Latin American patients with AML who are not eligible for intensive induction chemotherapy. Our findings pave the first steps of the way to describe, understand, and support informed decision-making processes in our region.</description><issn>0123-2576</issn><issn>2500-7106</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNo1kMtKAzEUhoMoWLRL9-cFUjOTuborxRsU3NT1kGRObDSTlCRjmXfyIZ16WZ0DP__Hz0fITcZWvOJNccuynOdlXa2qhp-RRV4yRuuMVedkcYroKbskyxjfGWN5m_OGsQX52gUUaUCX4CBSwuAiCNeDssYZJSz4MSk_YATjQKgxIQwTWm96sDh-4GDEqWhmQITj3oMICM4nQGvejLQI2oe5m9BF84nz148qGe9A7XHwaY9BHKY7WMO8w9KjD7aHmMZ-Ah38ANuZ7eh6wDCvuSYXWtiIy797RV4f7nebJ7p9eXzerLdUZUXNKcoa275oRINZmysmsUWZYy5lrWXBesUZ8kJxbKpWY4Z9ycsyK4WqdSmk1PyK0F-uCj7GgLo7BDOIMHUZ635sd_-2u9k2_wZ9qHdp</recordid><startdate>20231001</startdate><enddate>20231001</enddate><creator>Gálvez-Cárdenas, Kenny Mauricio</creator><creator>Enciso-Olivera, Leonardo José</creator><creator>Samanez-Figari, César Augusto</creator><creator>Quintana-Truyenque, Shirley</creator><creator>Castillo-Ríos, Benito Arturo</creator><creator>Quintero-Vega, Guillermo Enrique</creator><creator>Arrieta-López, Elizabeth</creator><creator>Pinto-Gómez, Alexis Javier</creator><creator>Aruachan-Vesga, Sandra</creator><creator>Durán-Sánchez, María Isabel</creator><creator>Espino-Lopéz, Germán</creator><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0003-4002-1423</orcidid><orcidid>https://orcid.org/0000-0001-5540-1969</orcidid><orcidid>https://orcid.org/0000-0002-3671-6911</orcidid><orcidid>https://orcid.org/0000-0002-1879-2486</orcidid><orcidid>https://orcid.org/0000-0003-1192-9053</orcidid><orcidid>https://orcid.org/0000-0003-3755-9513</orcidid><orcidid>https://orcid.org/0000-0002-3714-4476</orcidid></search><sort><creationdate>20231001</creationdate><title>Treatment patterns and clinical outcomes in acute myeloid leukemia patients who are not eligible for intensive induction chemotherapy: A real-world study from Latin-America</title><author>Gálvez-Cárdenas, Kenny Mauricio ; Enciso-Olivera, Leonardo José ; Samanez-Figari, César Augusto ; Quintana-Truyenque, Shirley ; Castillo-Ríos, Benito Arturo ; Quintero-Vega, Guillermo Enrique ; Arrieta-López, Elizabeth ; Pinto-Gómez, Alexis Javier ; Aruachan-Vesga, Sandra ; Durán-Sánchez, María Isabel ; Espino-Lopéz, Germán</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1473-eb7e9d48a8e192c0be9eb2e2bb7fb40dc30e34c3e869fe1ed535515ac7f5abbf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gálvez-Cárdenas, Kenny Mauricio</creatorcontrib><creatorcontrib>Enciso-Olivera, Leonardo José</creatorcontrib><creatorcontrib>Samanez-Figari, César Augusto</creatorcontrib><creatorcontrib>Quintana-Truyenque, Shirley</creatorcontrib><creatorcontrib>Castillo-Ríos, Benito Arturo</creatorcontrib><creatorcontrib>Quintero-Vega, Guillermo Enrique</creatorcontrib><creatorcontrib>Arrieta-López, Elizabeth</creatorcontrib><creatorcontrib>Pinto-Gómez, Alexis Javier</creatorcontrib><creatorcontrib>Aruachan-Vesga, Sandra</creatorcontrib><creatorcontrib>Durán-Sánchez, María Isabel</creatorcontrib><creatorcontrib>Espino-Lopéz, Germán</creatorcontrib><collection>CrossRef</collection><jtitle>Medicina y Laboratorio</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gálvez-Cárdenas, Kenny Mauricio</au><au>Enciso-Olivera, Leonardo José</au><au>Samanez-Figari, César Augusto</au><au>Quintana-Truyenque, Shirley</au><au>Castillo-Ríos, Benito Arturo</au><au>Quintero-Vega, Guillermo Enrique</au><au>Arrieta-López, Elizabeth</au><au>Pinto-Gómez, Alexis Javier</au><au>Aruachan-Vesga, Sandra</au><au>Durán-Sánchez, María Isabel</au><au>Espino-Lopéz, Germán</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment patterns and clinical outcomes in acute myeloid leukemia patients who are not eligible for intensive induction chemotherapy: A real-world study from Latin-America</atitle><jtitle>Medicina y Laboratorio</jtitle><date>2023-10-01</date><risdate>2023</risdate><volume>27</volume><issue>4</issue><spage>315</spage><epage>332</epage><pages>315-332</pages><issn>0123-2576</issn><eissn>2500-7106</eissn><abstract>Introduction. There is a knowledge gap concerning patients with acute myeloid leukemia (AML) who are not eligible for intensive induction chemotherapy; this, together with a recent increase in the incidence in Latin America, encloses a need. Through real-world evidence, we describe and compare the results of the different treatment strategies within this context. Methodology. This is a longitudinal, descriptive, retrospective study of a cohort of Latin American patients with AML not eligible for intensive induction chemotherapy, treated with low-intensity chemotherapy or with the best supportive care alone between January 1, 2015, to December 31, 2018. Results. Of a total of 125 patients (median age 74.8 years), the majority received low-intensity chemotherapy (78.4%). The median time in months of overall survival (9.2), progression-free survival (4.8), and time to treatment failure (3.8) were longer in patients receiving hypomethylating agents. Additionally, better results were observed with low-intensity chemotherapy (complete response 11.2% and stable disease 17.3%) compared to the best supportive care alone. Conclusion. We deliver a real-world standpoint of Latin American patients with AML who are not eligible for intensive induction chemotherapy. Our findings pave the first steps of the way to describe, understand, and support informed decision-making processes in our region.</abstract><doi>10.36384/01232576.683</doi><tpages>18</tpages><orcidid>https://orcid.org/0000-0003-4002-1423</orcidid><orcidid>https://orcid.org/0000-0001-5540-1969</orcidid><orcidid>https://orcid.org/0000-0002-3671-6911</orcidid><orcidid>https://orcid.org/0000-0002-1879-2486</orcidid><orcidid>https://orcid.org/0000-0003-1192-9053</orcidid><orcidid>https://orcid.org/0000-0003-3755-9513</orcidid><orcidid>https://orcid.org/0000-0002-3714-4476</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0123-2576
ispartof Medicina y Laboratorio, 2023-10, Vol.27 (4), p.315-332
issn 0123-2576
2500-7106
language eng
recordid cdi_crossref_primary_10_36384_01232576_683
source DOAJ Directory of Open Access Journals; Alma/SFX Local Collection
title Treatment patterns and clinical outcomes in acute myeloid leukemia patients who are not eligible for intensive induction chemotherapy: A real-world study from Latin-America
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T07%3A19%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20patterns%20and%20clinical%20outcomes%20in%20acute%20myeloid%20leukemia%20patients%20who%20are%20not%20eligible%20for%20intensive%20induction%20chemotherapy:%20A%20real-world%20study%20from%20Latin-America&rft.jtitle=Medicina%20y%20Laboratorio&rft.au=G%C3%A1lvez-C%C3%A1rdenas,%20Kenny%20Mauricio&rft.date=2023-10-01&rft.volume=27&rft.issue=4&rft.spage=315&rft.epage=332&rft.pages=315-332&rft.issn=0123-2576&rft.eissn=2500-7106&rft_id=info:doi/10.36384/01232576.683&rft_dat=%3Ccrossref%3E10_36384_01232576_683%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true